Clinical Trials Logo
  1. Home
  2. HIV-1 Infections
  3. NCT01013415

CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients — CD4-ZETA  

HIV-1 Infections Clinical Trial

Official title:
A Phase I/II Study Of the Safety, Survival, and Trafficking of Autologous CD4-ZETA Gene-Modified T Cells With and Without Extension Interleukin-2 in HIV Infected Patients

Clinical Trial Summary

The purpose of this study is to find out the safety and activity of an experimental anti-HIV treatment using autologous CD4-zeta gene-changed T cells and/or IL-2 (recombinant interleukin2).

Clinical Trial Description

The purpose of this study is to find out the safety and activity of an experimental anti-HIV treatment using autologous CD4-zeta gene-changed T cells and/or IL-2 (recombinant interleukin2). The treatments that the investigators are studying try to improve the immune system by changing some of your T cells so they can find and destroy HIV infected cells (HIV is usually able to hide from your T cells). In this study, the investigators are also trying to find out if giving you more IL-2 at the same time as gene changed T cells will help the T cells to live longer or fight HIV better. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01013415
Study type Interventional
Source University of Pennsylvania
Contact
Status Completed
Phase Phase 1
Start date September 2001
Completion date August 2021
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02923713 - TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV Phase 2
Completed NCT01151319 - Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults Phase 1
Completed NCT01138605 - TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV Phase 2
Completed NCT01078233 - Observational Data Analysis in EuroSIDA (MK-0518-058)
Recruiting NCT02593409 - HIV PrEP Priming of Immune Effectors Phase 4
Completed NCT00557245 - Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples Phase 3
Withdrawn NCT00984152 - Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women Phase 3
Completed NCT00799058 - A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States Phase 1/Phase 2
Completed NCT01159275 - Lopinavir (LPV) Dose Reduction Phase 1/Phase 2
Completed NCT01281813 - TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV Phase 3
Completed NCT01078246 - Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268)
Active, not recruiting NCT03027297 - TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV Phase 3
Completed NCT01033760 - Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM) Phase 3
Completed NCT01139905 - Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children Phase 2
Completed NCT00830804 - Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults Phase 2
Completed NCT01074931 - Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China N/A